Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819000 · ClinicalTrials.gov registry record
Therapy Optimization in Multiple Sclerosis (MS)
A clinical trial of Multiple Sclerosis, sponsored by Teva Neuroscience.
- Completed
- Registry status
- 2,878
- Enrollment target
- 3
- Study locations
NCT00819000: Completed study of Multiple Sclerosis, sponsored by Teva Neuroscience.
NCT00819000 is a study of Multiple Sclerosis that has completed, run by Teva Neuroscience. The registered enrollment target is 2,878 participants, above the 576-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (400% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00819000, a study of Multiple Sclerosis, has completed, sponsored by Teva Neuroscience.
- COMPLETED
- Registry status
- 2,878 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
Conditions Studied
Interventions
- DRUG Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
Study Locations (3)
Michigan
- Teva Investigational Site - Swartz Creek
Ohio
- Teva Investigational Site - Columbus
Pennsylvania
- Teva Investigational Site - Carnegie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,878 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-01 |
What the finished NCT00819000 record still lists
NCT00819000 is an observational study that tracks outcomes without assigning an intervention. Its 2,878 participants enrollment target places it among the larger protocols in the corpus, above the 576-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (400% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b is the first listed.
NCT00819000 reports a single indexed study location in Michigan, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00819000 about?
NCT00819000 is a clinical study titled "Therapy Optimization in Multiple Sclerosis (MS)". The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
What is the current status of trial NCT00819000?
This trial is currently completed. The enrollment target is 2,878 participants. The study started on 2008-12. Estimated completion is 2013-01.
What conditions does trial NCT00819000 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT00819000?
The interventions under investigation include: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b (DRUG).
Who is sponsoring clinical trial NCT00819000?
This trial is sponsored by Teva Neuroscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00819000 being conducted?
This trial has 3 study locations across Michigan, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00819000's enrollment target sits among peer trials
2,878 12th of 315 higher than 304 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia